Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | DRD3 | P35462 | 6/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526261 | 0.81 | HTR1A (0.54) | HTR1ADRD2DRD3 | |
| SCHEMBL7908016 | 0.81 | OPRD1 (0.38) | HTR1ADRD2DRD3OPRM1OPRD1 | |
| SCHEMBL9310382 | 0.69 | GRIN2D (0.36) | HTR1ADRD2DRD3 | |
| SCHEMBL7908075 | 0.68 | HTR1A (0.48) | HTR1ADRD2DRD3 | |
| SCHEMBL9674604 | 0.66 | HTR1A (0.55) | HTR1ADRD2DRD3 | |
| SCHEMBL9676122 | 0.64 | HTR1A (0.51) | HTR1ADRD2DRD3 | |
| SCHEMBL7905525 | 0.63 | HTR1A (0.47) | HTR1ADRD2DRD3 | |
| SCHEMBL9676250 | 0.63 | HTR1A (0.47) | HTR1ADRD2DRD3 | |
| SCHEMBL9674292 | 0.63 | HTR1A (0.53) | HTR1ADRD2DRD3 | |
| SCHEMBL7896192 | 0.59 | ALOX5 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6201119-B1 | 2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPIN-9-AMINE COMPOUNDS USEFUL AS INTERMEDIATES TO ANTIVIRALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-13 | — | — | US | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| US-5270464-A | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-14 | — | — | US | disclosed |
| EP-0538297-A1 | ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000979-A1 | ANTIVIRAL TETRAHYDROIMIDAZO[1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |